Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivoSim LabsFRA:4OR 33 PS Ratio is 81.21 as of Aug. 09, 2026, which is 136% above its 10-year median of 34.48. GuruFocus rates FRA:4OR with a GF Score™ of 33/100 and a GF Value™ of €15.74. The stock has 6 warning signs investors should review. Among 931 Biotechnology companies, VivoSim Labs ranks better than 51.02% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, VivoSim Labs's share price is €3.492.
VivoSim Labs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.04. Hence, VivoSim Labs's PS Ratio for today is 81.21.
The historical rank and industry rank for VivoSim Labs's PS Ratio or its related term are showing as below:
FRA:4OR'
s PS Ratio Range Over the Past 10 Years
Min: 6.76 Med: 34.48 Max: 424.6
Current: 9.18
During the past 13 years, VivoSim Labs's highest PS Ratio was 424.60. The lowest was 6.76. And the median was 34.48.
FRA:4OR's PS Ratio is ranked better than 51.02% of 931
companies
in the Biotechnology industry
Industry Median: 9.43
vs FRA:4OR: 9.18
VivoSim Labs Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of VivoSim Labs was -48.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -53.60% per year.
During the past 13 years, VivoSim Labs's highest 3-Year average Revenue per Share Growth Rate was 103.00% per year. The lowest was -63.80% per year. And the median was -26.90% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
VivoSim Labs PS Ratio Related Terms
VivoSim Labs PS Ratio Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VivoSim Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
VivoSim Labs's PS Ratio for today is calculated as
VivoSim Labs's Share Price of today is €3.492. VivoSim Labs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
VivoSim Labs (FRA:4OR) has a PS Ratio of 81.21 as of Aug. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on VivoSim Labs and its competitors. This is 136% above median its historical median of 34.48. Over the past decade, VivoSim Labs' PS Ratio has ranged from 6.76 to 424.60. According to the industry distribution chart, VivoSim Labs ranks #456 out of 931 companies in the Biotechnology industry, placing it in the top 49%.
Is VivoSim Labs' PS Ratio too high?
VivoSim Labs' current PS Ratio of 81.21 is 136% above median its 10-year median of 34.48. Over the past 10 years, this metric has ranged from a low of 6.76 to a high of 424.60. The Biotechnology industry median PS Ratio is 9.43. VivoSim Labs' value of 81.21 is 761.2% above this industry median. Based on the distribution chart, VivoSim Labs ranks #456 out of 931 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' PS Ratio compare to MTNB and HEPA?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #456 out of 931 companies for PS Ratio. This puts VivoSim Labs in the upper half of its industry. The industry median PS Ratio is 9.43. VivoSim Labs' value of 81.21 is 761.2% above this benchmark. Historically, VivoSim Labs' own PS Ratio has ranged from 6.76 to 424.60 over the past decade. While the company's 10-year median is 34.48 vs. the industry median of 9.43, VivoSim Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.43, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current PS Ratio of 81.21 is 761.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median PS Ratio is 9.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current PS Ratio is 81.21, which is 136% above median its own 10-year median of 34.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current PS Ratio of 81.21. The stock's GF Value™ is €15.74, compared to a current price of €3.49 — trading 77.8% below its estimated fair value. The current PS Ratio is 81.21, which is 136% above median its 10-year median of 34.48 and 761.2% above the Biotechnology industry median of 9.43. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current PS Ratio is 81.21 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 77.8% below its estimated GF Value™ of €15.74.
Key valuation signals for FRA:4OR:
PS Ratio: 81.21 (136% above median its 10-year median of 34.48)
GF Value™: €15.74 vs. price of €3.49 (77.8% below fair value)
Industry Position: 761.2% above the Biotechnology median (#456 of 931)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score
Get the complete analysis for FRA:4OR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
